La dolce vita: fueling chimeric antigen receptor (CAR) T cells with Glut1 to improve therapeutic efficacy-Immunometabolism-CSCIED科技核心评价数据库-手机版

La dolce vita: fueling chimeric antigen receptor (CAR) T cells with Glut1 to improve therapeutic efficacy

La dolce vita: fueling chimeric antigen receptor (CAR) T cells with Glut1 to improve therapeutic efficacy

ES评分 0 浏览量：1044 下载量：0

DOI	10.1097/IN9.0000000000000055
刊名	Immunometabolism IJ
年，卷(期)	2025, 7(1)
作者	Slattery, Karen; Finlay, David K.; Darcy, Phillip K.,
作者单位	[Slattery, Karen] St James Hosp, Trinity Translat Med Inst, Sch Med, Dublin, Ireland; [Finlay, David K.] Trinity Coll Dublin, Sch Biochem & Immunol, Trinity Biomed Sci, Dublin, Ireland; [Finlay, David K.] Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, T
摘要	The approval of chimeric antigen receptor (CAR) T cell therapies for the treatment of hematological cancers has marked a new era in cancer care, with seven products being FDA approved since 2017. However, challenges remain, and while profound effects are observed initially in myeloma, the majority of patients relapse, which is concomitant with poor CAR T cell persistence. Similarly, the efficacy of CAR T cell therapy is limited in solid tumors, largely due to tumor antigen heterogeneity, immune evasion mechanisms, and poor infiltration and persistence. In this recent study, Guerrero et al endeavor to improve the efficacy of human CAR T cells by overexpressing the glucose transporter GLUT1 and show that GLUT1 overexpressing CAR T cells have improved capacity to persist and control tumor burden in vivo.
Abstract	The approval of chimeric antigen receptor (CAR) T cell therapies for the treatment of hematological cancers has marked a new era in cancer care, with seven products being FDA approved since 2017. However, challenges remain, and while profound effects are observed initially in myeloma, the majority of patients relapse, which is concomitant with poor CAR T cell persistence. Similarly, the efficacy of CAR T cell therapy is limited in solid tumors, largely due to tumor antigen heterogeneity, immune evasion mechanisms, and poor infiltration and persistence. In this recent study, Guerrero et al endeavor to improve the efficacy of human CAR T cells by overexpressing the glucose transporter GLUT1 and show that GLUT1 overexpressing CAR T cells have improved capacity to persist and control tumor burden in vivo.
关键词	chimeric antigen receptor T cells; metabolism; cancer; tumor; Glut1; glucose; glycolysis; cytokines
KeyWord	chimeric antigen receptor T cells; metabolism; cancer; tumor; Glut1; glucose; glycolysis; cytokines
基金项目
页码	1-3

参考文献
相关文献

[1]. Ma S, Ming Y, Wu J, et al. Cellular metabolism regulates the differentiation and function of T-cell subsets. Cell Mol Immunol. 2024;21(5):419-35.

[2]. Nanjireddy PM, Olejniczak SH, Buxbaum NP. Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes. Front Immunol. 2023;14:1121565.

[3]. Guerrero JA, Klysz DD, Chen Y, et al. GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency. Nat Commun. 2024;15(1):8658.

[4]. Ma EH, Verway MJ, Johnson RM, et al. Metabolic profiling using stable isotope tracing reveals distinct patterns of glucose utilization by physiologically activated CD8(+) T cells. Immunity. 2019;51(5):856-70.e5.

[5]. Ma EH, Dahabieh MS, DeCamp LM, et al. (13)C metabolite tracing reveals glutamine and acetate as critical in vivo fuels for CD8 T cells. Sci Adv. 2024;10(22):eadj1431.

[6]. Shi Y, Kotchetkov IS, Dobrin A, et al. GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy. Mol Ther. 2024;32(7):2393-405.

[7]. Sinclair LV, Barthelemy C, Cantrell DA. Single cell glucose uptake assays: a cautionary tale. Immunometabolism. 2020;2(4):e200029.

[8]. Tsuchiya M, Tachibana N, Hamachi I. Post-click labeling enables highly accurate single cell analyses of glucose uptake ex vivo and in vivo. Commun Biol. 2024;7(1):459.

[9]. Toledano Zur R, Atar O, Barliya T, et al. Genetically engineering glycolysis in T cells increases their antitumor function. J ImmunoTher Cancer. 2024;12(7):e008434.

[10]. Feng B, Bai Z, Zhou X, et al. The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8(+) T cells against cancer. Nature. 2024;634(8034):712-20.

[11]. Kuen DS, Kim BS, Chung Y. IL-17-producing cells in tumor immunity: friends or foes? Immune Netw. 2020;20(1):e6.

[12]. Chang CH, Qiu J, O’Sullivan D, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229-41.

[13]. Abbott KL, Ali A, Reinfeld BI, et al. Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability. Elife. 2024;13:RP95652.

[14]. Reinfeld BI, Madden MZ, Wolf MM, et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature. 2021;593(7858):282-8.

[15]. Siska PJ, Beckermann KE, Mason FM, et al. Mitochondrial dysregulation and glycolytic insufficiency functionally impair CD8 T cells infiltrating human renal cell carcinoma. JCI Insight. 2017;2(12):e93411.

[16]. Holman GD. Structure, function and regulation of mammalian glucose transporters of the SLC2 family. Pflugers Arch. 2020;472(9):1155-75.

[17]. Qualls-Histed SJ, Nielsen CP, MacGurn JA. Lysosomal trafficking of the glucose transporter GLUT1 requires sequential regulation by TXNIP and ubiquitin. iScience. 2023;26(3):106150.

[18]. Chan JD, Scheffler CM, Munoz I, et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature. 2024;629(8010):201-10.

[19]. Doan A, Mueller KP, Chen A, et al. FOXO1 is a master regulator of CAR T memory programming. Nature. 2024;629(8010):211-8.

[20]. van Bruggen JAC, Martens AWJ, Fraietta JA, et al. Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8(+) T cells and impede CAR T-cell efficacy. Blood. 2019;134(1):44-58.,

引用本文

Slattery, Karen; Finlay, David K.; Darcy, Phillip K.. La dolce vita: fueling chimeric antigen receptor (CAR) T cells with Glut1 to improve therapeutic efficacy [J]. Immunometabolism. 2025; 7; (1). 1 - 3.

文献评论

相关学者

相关机构